Comparative analysis of enzymatically produced novel linear DNA constructs with plasmids for use as DNA vaccines

Gene Therapy

Volumn 21, Issue 7, 2014, Pages 645-652

  Walters, A A ^a,c   Kinnear, E ^a   Shattock, R J ^a   Mcdonald, J U ^a   Caproni, L J ^b   Porter, N ^b   Tregoning, J S ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b LEATHERHEAD FOOD RESEARCH   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; DOUBLE STRANDED DNA; ENVELOPE PROTEIN; GLYCOPROTEIN GP 140; INFLUENZA VACCINE; LUCIFERASE; PLASMID DNA; VIRUS HEMAGGLUTININ; DNA; GP140 ENVELOPE PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; POLYADENYLIC ACID; VIRUS ENVELOPE PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DNA IMMUNIZATION; GENE CASSETTE; GENE CONSTRUCT; GENE EXPRESSION; GENE TARGETING; HUMAN IMMUNODEFICIENCY VIRUS; HUMORAL IMMUNITY; IMMUNOGENICITY; INFLUENZA A (H1N1); INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; MDCK CELL LINE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; SCALE UP; TELOMERE; VACCINE PRODUCTION; VIRUS IMMUNITY; ADMINISTRATION AND DOSAGE; ANIMAL; BAGG ALBINO MOUSE; CHO CELL LINE; COMPARATIVE STUDY; CRICETULUS; DOG; FEMALE; GENE VECTOR; GENETICS; IMMUNOLOGY; INFLUENZA A VIRUS (H1N1); MOUSE; ORTHOMYXOVIRUS INFECTION; PHYSIOLOGY; PLASMID; VACCINATION; VIROLOGY;

BACTERIA (MICROORGANISMS); MUS;

ANIMALS; CHO CELLS; CRICETULUS; DNA; DOGS; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; FEMALE; GENETIC VECTORS; HEMAGGLUTININS, VIRAL; INFLUENZA A VIRUS, H1N1 SUBTYPE; MADIN DARBY CANINE KIDNEY CELLS; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; PLASMIDS; POLY A; PROMOTER REGIONS, GENETIC; TELOMERE; VACCINATION; VACCINES, DNA;

EID: 84903908289     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2014.37     Document Type: Article

References (37)

1. Tang DC, DeVit M, Johnston SA. Genetic immunization is a simple method for eliciting an immune response. Nature 1992; 356: 152-154
2. Gurunathan S, Klinman DM, Seder RA. DNA vaccines: Immunology, application, and optimization. Ann Rev Immunol 2000; 18: 927-974
3. Evensen O, Leong JA. DNA vaccines against viral diseases of farmed fish. Fish Shellfish Immunol 2013; 35: 1751-1758
4. Liu MA. DNA vaccines: An historical perspective and view to the future. Immunol Rev 2011; 239: 62-84
5. Ferraro B, Morrow MP, Hutnick NA, Shin TH, Lucke CE, Weiner DB. Clinical applications of DNA vaccines: Current progress. Clin Infect Dis 2011; 53: 296-302
6. Klinman DM, Klaschik S, Tross D, Shirota H, Steinhagen F. FDA guidance on prophylactic DNA vaccines: Analysis and recommendations. Vaccine 2010; 28: 2801-2805
7. Belakova J, Horynova M, Krupka M, Weigl E, Raska M. DNA vaccines: Are they still just a powerful tool for the future?. Arch Immunol Ther Exp 2007; 55: 387-398
8. Luke JM, Vincent JM, Du SX, Gerdemann U, Leen AM, Whalen RG, et al. Improved antibiotic-free plasmid vector design by incorporation of transient expression enhancers. Gene Ther 2011; 18: 334-343
9. Luke J, Carnes AE, Hodgson CP, Williams JA. Improved antibiotic-free DNA vaccine vectors utilizing a novel RNA based plasmid selection system. Vaccine 2009; 27: 6454-6459
10. Mairhofer J, Cserjan-Puschmann M, Striedner G, Nöbauer K, Razzazi-Fazeli E, Grabherr R. Marker-free plasmids for gene therapeutic applications-Lack of antibiotic resistance gene substantially improves the manufacturing process. J Biotechnol 2010; 146: 130-137
11. van der Heijden I, Gomez-Eerland R, van den Berg JH, Oosterhuis K, Schumacher TN, Haanen JB, et al. Transposon leads to contamination of clinical pDNA vaccine. Vaccine 2013; 31: 3274-3280
12. Prather KJ, Sagar S, Murphy J, Chartrain M. Industrial scale production of plasmid DNA for vaccine and gene therapy: Plasmid design, production, and purification. Enzyme Microb Tech 2003; 33: 865-883
13. Darquet AM, Cameron B, Wils P, Scherman D, Crouzet J. A new DNA vehicle for nonviral gene delivery: Supercoiled minicircle. Gene Therapy 1997; 4: 1341-1349
14. Moreno S, Lopez-Fuertes L, Vila-Coro AJ, Sack F, Smith CA, Konig SA, et al. DNA immunisation with minimalistic expression constructs. Vaccine 2004; 22: 1709-1716
15. Kay MA, He CY, Chen ZY. A robust system for production of minicircle DNA vectors. Nat Biotechnol 2010; 28: 1287-1289
16. Hill V (Inventor; Touchlight Genetics Ltd, assignee). Production of Closed Linear DNA. WO 2010086626 A1, 5 August 2010
17. Heinrich J, Schultz J, Bosse M, Ziegelin G, Lanka E, Moelling K. Linear closed mini DNA generated by the prokaryotic cleaving-joining enzyme TelN is functional in mammalian cells. J Mol Med 2002; 80: 648-654
18. Huang X, Jin W, Hu K, Luo S, Du T, Griffin GE, et al. Highly conserved HIV-1 gp120 glycans proximal to CD4-binding region affect viral infectivity and neutralizing antibody induction. Virology 2012; 423: 97-106
19. Kopycinski J, Cheeseman H, Ashraf A, Gill D, Hayes P, Hannaman D, et al. A DNA-based candidate HIV vaccine delivered via in vivo electroporation induces CD4 responses toward the alpha4beta7-binding V2 loop of HIV gp120 in healthy volunteers. Clin Vaccine Immunol 2012; 19: 1557-1559
20. Rosazza C, Buntz A, Riess T, Woll D, Zumbusch A, Rols MP. Intracellular tracking of single plasmid DNA-particles after delivery by electroporation. Mol Ther 2013; 2112: 2217-2226
21. Yin W, Xiang P, Li Q. Investigations of the effect of DNA size in transient transfection assay using dual luciferase system. Anal Biochem 2005; 346: 289-294
22. Zhang G, Ludtke JJ, Thioudellet C, Kleinpeter P, Antoniou M, Herweijer H, et al. Intraarterial delivery of naked plasmid DNA expressing full-length mouse dystrophin in the mdx mouse model of duchenne muscular dystrophy. Hum Gene Ther 2004; 15: 770-782
23. von Groll A, Levin Y, Barbosa MC, Ravazzolo AP. Linear DNA low efficiency transfection by liposome can be improved by the use of cationic lipid as charge neutralizer. Biotechnol Prog 2006; 22: 1220-1224
24. Darquet AM, Rangara R, Kreiss P, Schwartz B, Naimi S, Delaere P, et al. Minicircle: An improved DNA molecule for in vitro and in vivo gene transfer. Gene Therapy 1999; 6: 209-218
25. Madeira C, Rodrigues CA, Reis MS, Ferreira FF, Correia RE, Diogo MM, et al. Nonviral gene delivery to neural stem cells with minicircles by microporation. Biomacromolecules 2013; 14: 1379-1387
26. Chen ZY, He CY, Ehrhardt A, Kay MA. Minicircle DNA vectors devoid of bacterial DNA result in persistent and high-level transgene expression in vivo. Mol Ther 2003; 8: 495-500
27. Endmann A, Baden M, Weisermann E, Kapp K, Schroff M, Kleuss C, et al. Immune response induced by a linear DNA vector: Influence of dose, formulation and route of injection. Vaccine 2010; 28: 3642-3649
28. Mann JF, McKay PF, Arokiasamy S, Patel RK, Klein K, Shattock RJ. Pulmonary delivery of DNA vaccine constructs using deacylated PEI elicits immune responses and protects against viral challenge infection. J Control Release 2013; 170: 452-459
29. Mann JF, McKay PF, Arokiasamy S, Patel RK, Tregoning JS, Shattock RJ. Mucosal application of gp140 encoding DNA polyplexes to different tissues results in altered immunological outcomes in Mice. PLoS One 2013; 8: E67412
30. Zhang C, Gao S, Jiang W, Lin S, Du F, Li Z, et al. Targeted minicircle DNA delivery using folate-poly(ethylene glycol)-polyethylenimine as non-viral carrier. Biomaterials 2010; 31: 6075-6086
31. Vaysse L, Gregory LG, Harbottle RP, Perouzel E, Tolmachov O, Coutelle C. Nuclear-Targeted minicircle to enhance gene transfer with non-viral vectors in vitro and in vivo. J Gene Med 2006; 8: 754-763
32. Hutnick NA, Myles DJ, Bian CB, Muthumani K, Weiner DB. Selected approaches for increasing HIV DNA vaccine immunogenicity in vivo. Curr Opin Virol 2011; 1: 233-240
33. Lopez-Fuertes L, Perez-Jimenez E, Vila-Coro AJ, Sack F, Moreno S, Konig SA, et al. DNA vaccination with linear minimalistic (MIDGE) vectors confers protection against Leishmania major infection in mice. Vaccine 2002; 21: 247-257
34. Smith HA. Regulatory considerations for nucleic acid vaccines. Vaccine 1994; 12: 1515-1519
35. Donnelly L, Curran RM, Tregoning JS, McKay PF, Cole T, Morrow RJ, et al. Intravaginal immunization using the recombinant HIV-1 clade-C trimeric envelope glycoprotein CN54gp140 formulated within lyophilized solid dosage forms. Vaccine 2011; 29: 4512-4520
36. Elleman CJ, Barclay WS. The M1 matrix protein controls the filamentous phenotype of influenza A virus. Virology 2004; 321: 144-153
37. Tregoning JS, Yamaguchi Y, Wang B, Mihm D, Harker JA, Bushell ES, et al. Genetic susceptibility to the delayed sequelae of neonatal respiratory syncytial virus infection is MHC dependent. J Immunol 2010; 185: 5384-5391.